Clinical Trials
4
Active:2
Completed:1
Trial Phases
3 Phases
Early Phase 1:2
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Early Phase 1
2 (50.0%)Not Applicable
1 (25.0%)Phase 1
1 (25.0%)A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Early Phase 1
Active, not recruiting
- Conditions
- Neuroendocrine TumorsNeuroendocrine Tumor of the LungNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Tumor of Pancreas
- Interventions
- Drug: [212Pb] VMT-α-NETDiagnostic Test: [203Pb] VMT-α-NET SPECT/CT
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- David Bushnell
- Target Recruit Count
- 24
- Registration Number
- NCT06148636
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
Phase 1
Withdrawn
- Conditions
- Gastro-enteropancreatic Neuroendocrine TumorNeuroendocrine Tumors
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- David Bushnell
- Registration Number
- NCT04614766
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
Early Phase 1
Active, not recruiting
- Conditions
- Neuroendocrine Tumor Gastrointestinal, Hormone-SecretingNeuroendocrine Tumor, Malignant
- Interventions
- Drug: 90Y-DOTA-3-Tyr-OctreotideDrug: 131I-MIBG
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- David Bushnell
- Target Recruit Count
- 20
- Registration Number
- NCT03044977
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Combination Targeted Radiotherapy in Neuroendocrine Tumors
Not Applicable
Completed
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2010-04-06
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- David Bushnell
- Target Recruit Count
- 2
- Registration Number
- NCT01099228
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Department of Veteran Affairs Medical Center, Iowa City, Iowa, United States
News
No news found